Stock Analiz

Rafael Holdings, Inc. RFL

Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026

$1.07Market cap $56M
Open the interactive analysis →

Rafael Holdings, Inc. (RFL) is a healthcare company listed in the US with a market value of about $56M. In fiscal year 2026 it had revenue of $874000 and net income of -$30M, a net margin of -3390.7%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 2% a year, a 5-year average ROIC of -50%.

About Rafael

Rafael is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $6M in 2016 to $874000 in 2026, a decline of about 16.9% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 121% over three years (dilution for shareholders). It spends 2784% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S63.9
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-53.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-4.7%
Revenue growth (5 yrs, per year)1.7%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-8639.5%
ROIC (5-yr avg.)-50.3%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal year2026202520242023202220212020201920182017
Revenue$874000$917000$637000$279000$410000$802000$5M$5M$4M$6M
Net income-$30M-$31M-$34M-$2M-$125M-$23M-$11M-$5M-$12M$138000
Free cash flow-$30M-$19M-$8M—-$26M-$16M-$5M-$4M-$3M-$3M
EPS (diluted)$-0.58$-1.04$-1.45$-0.08$-6.31$-1.49$-0.66$-0.35$-0.93$0.01
Net margin-3390.7%-3328.2%-5401.9%-672.4%-30404.4%-2875.4%-219.0%-95.2%-266.5%2.5%
ROIC-49.9%-28.0%-117.5%-14.6%-41.4%-16.3%-5.7%-6.0%-2.8%0.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Rafael pay a dividend?

Not currently.

Is Rafael a good stock to buy?

We do not give buy or sell advice. Rafael scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.